Tricida to Present at the Needham Virtual Healthcare Conference

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 12:45 pm PT. The company will present a business update and its key initiatives. A live webcast will be available on the Tricida website, with an archived version accessible for 90 days post-presentation. Tricida focuses on developing veverimer, an investigational drug aimed at treating metabolic acidosis in chronic kidney disease (CKD) patients. This condition affects around three million CKD patients in the U.S.

News Market Reaction – TCDA

-3.13%

-3.13% Session move

In the trading session that priced this news, TCDA declined 3.13%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20^th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives.

A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows progression of CKD in patients with metabolic acidosis and CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.tricida.com.

Contact:

Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

FAQ

When is Tricida presenting at the Needham Virtual Healthcare Conference?

Tricida will present on April 13, 2021, at 12:45 pm PT.

What will Tricida discuss at the conference?

Tricida will provide a company overview, business update, and progress on key initiatives.

Where can I watch Tricida's presentation?

The presentation can be streamed live on the Tricida website.

What is veverimer's purpose in Tricida's pipeline?

Veverimer is designed to treat metabolic acidosis in patients with chronic kidney disease.

How many people in the U.S. are affected by metabolic acidosis related to CKD?

Approximately three million patients with chronic kidney disease are affected.